Merck Income Statement Research

MRK Stock

USD 126.88 0.06 0.05%

Most accounts from Merck's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Merck Company current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Merck Valuation and Merck Correlation analysis.

At this time, Merck's Total Operating Expenses is quite stable compared to the past year. Income Tax Expense is expected to rise to about 2 B this year, although the value of Operating Income will most likely fall to about 2.8 B.

	2021	2022	2023	2024 (projected)
Gross Profit	35.1B	41.9B	43.9B	46.1B
Total Revenue	48.7B	59.3B	59.9B	32.5B

Gross Profit Total Revenue

Merck income statement Correlations

	Depreciation And Amortization	Interest Expense	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Research Development	Selling General Administrative	Minority Interest	Net Income From Continuing Ops	Non Recurring	Non Operating Income Net Other	Selling And Marketing Expenses	Tax Provision	Interest Income	Net Interest Income	Reconciled Depreciation	Extraordinary Items
Depreciation And Amortization		0.21	0.47	0.13	0.24	0.41	-0.09	0.35	0.76	0.04	0.28	0.02	0.2	0.28	-0.24	0.93	-0.26	-0.47	0.14	-0.31	0.49	-0.29	0.05	0.5	0.52	-0.48
Interest Expense	0.21		0.76	0.97	0.96	0.23	0.34	0.41	0.68	0.92	0.14	-0.03	0.11	0.2	0.8	0.42	-0.36	-0.21	-0.68	-0.69	-0.62	0.41	-0.15	-0.58	-0.59	0.49
Total Revenue	0.47	0.76		0.78	0.69	0.62	0.43	0.61	0.9	0.55	0.48	0.1	0.48	0.18	0.37	0.56	-0.21	-0.15	-0.52	-0.65	-0.42	0.22	0.0	-0.43	-0.27	0.38
Gross Profit	0.13	0.97	0.78		0.95	0.32	0.4	0.44	0.65	0.91	0.19	-0.04	0.2	0.11	0.81	0.35	-0.24	-0.07	-0.73	-0.69	-0.66	0.38	-0.02	-0.68	-0.66	0.56
Other Operating Expenses	0.24	0.96	0.69	0.95		0.09	0.2	0.3	0.65	0.97	0.01	-0.06	-0.02	0.16	0.86	0.48	-0.34	-0.25	-0.63	-0.63	-0.51	0.34	-0.12	-0.51	-0.54	0.43
Operating Income	0.41	0.23	0.62	0.32	0.09		0.59	0.73	0.6	-0.08	0.76	0.14	0.8	0.14	-0.26	0.31	0.08	0.22	-0.19	-0.4	-0.13	-0.04	0.41	-0.17	0.0	0.08
Ebit	-0.09	0.34	0.43	0.4	0.2	0.59		0.9	0.33	0.13	0.87	0.71	0.85	0.46	0.09	-0.12	0.05	0.69	-0.41	0.1	-0.48	0.07	0.33	-0.55	-0.43	0.42
Ebitda	0.35	0.41	0.61	0.44	0.3	0.73	0.9		0.64	0.14	0.94	0.68	0.89	0.56	-0.02	0.29	-0.06	0.45	-0.32	-0.05	-0.24	-0.06	0.33	-0.3	-0.18	0.18
Cost Of Revenue	0.76	0.68	0.9	0.65	0.65	0.6	0.33	0.64		0.45	0.5	0.16	0.47	0.29	0.19	0.79	-0.32	-0.26	-0.33	-0.57	-0.13	-0.01	0.01	-0.15	-0.03	0.12
Total Operating Expenses	0.04	0.92	0.55	0.91	0.97	-0.08	0.13	0.14	0.45		-0.15	-0.13	-0.17	0.09	0.96	0.31	-0.29	-0.22	-0.65	-0.56	-0.57	0.43	-0.16	-0.57	-0.63	0.48
Income Before Tax	0.28	0.14	0.48	0.19	0.01	0.76	0.87	0.94	0.5	-0.15		0.73	0.97	0.51	-0.29	0.16	0.1	0.51	-0.18	0.09	-0.15	-0.14	0.34	-0.22	-0.08	0.17
Total Other Income Expense Net	0.02	-0.03	0.1	-0.04	-0.06	0.14	0.71	0.68	0.16	-0.13	0.73		0.63	0.65	-0.16	-0.04	0.08	0.57	-0.01	0.6	-0.08	-0.14	0.15	-0.15	-0.11	0.18
Net Income	0.2	0.11	0.48	0.2	-0.02	0.8	0.85	0.89	0.47	-0.17	0.97	0.63		0.28	-0.3	0.07	0.22	0.58	-0.16	0.03	-0.22	-0.25	0.44	-0.31	-0.17	0.25
Income Tax Expense	0.28	0.2	0.18	0.11	0.16	0.14	0.46	0.56	0.29	0.09	0.51	0.65	0.28		0.0	0.3	-0.27	-0.01	-0.2	0.24	0.06	0.36	-0.14	0.16	0.16	-0.13
Research Development	-0.24	0.8	0.37	0.81	0.86	-0.26	0.09	-0.02	0.19	0.96	-0.29	-0.16	-0.3	0.0		0.05	-0.22	-0.11	-0.64	-0.43	-0.63	0.48	-0.17	-0.63	-0.7	0.53
Selling General Administrative	0.93	0.42	0.56	0.35	0.48	0.31	-0.12	0.29	0.79	0.31	0.16	-0.04	0.07	0.3	0.05		-0.33	-0.55	0.0	-0.42	0.31	-0.09	-0.09	0.36	0.34	-0.31
Minority Interest	-0.26	-0.36	-0.21	-0.24	-0.34	0.08	0.05	-0.06	-0.32	-0.29	0.1	0.08	0.22	-0.27	-0.22	-0.33		0.38	0.3	0.27	0.08	-0.24	0.72	-0.12	-0.2	0.04
Net Income From Continuing Ops	-0.47	-0.21	-0.15	-0.07	-0.25	0.22	0.69	0.45	-0.26	-0.22	0.51	0.57	0.58	-0.01	-0.11	-0.55	0.38		0.04	0.53	-0.22	-0.27	0.56	-0.43	-0.35	0.28
Non Recurring	0.14	-0.68	-0.52	-0.73	-0.63	-0.19	-0.41	-0.32	-0.33	-0.65	-0.18	-0.01	-0.16	-0.2	-0.64	0.0	0.3	0.04		0.53	0.72	-0.44	0.21	0.62	0.57	-0.57
Non Operating Income Net Other	-0.31	-0.69	-0.65	-0.69	-0.63	-0.4	0.1	-0.05	-0.57	-0.56	0.09	0.6	0.03	0.24	-0.43	-0.42	0.27	0.53	0.53		0.38	-0.29	0.17	0.3	0.27	-0.27
Selling And Marketing Expenses	0.49	-0.62	-0.42	-0.66	-0.51	-0.13	-0.48	-0.24	-0.13	-0.57	-0.15	-0.08	-0.22	0.06	-0.63	0.31	0.08	-0.22	0.72	0.38		-0.47	0.19	0.87	0.83	-0.91
Tax Provision	-0.29	0.41	0.22	0.38	0.34	-0.04	0.07	-0.06	-0.01	0.43	-0.14	-0.14	-0.25	0.36	0.48	-0.09	-0.24	-0.27	-0.44	-0.29	-0.47		-0.36	-0.29	-0.26	0.32
Interest Income	0.05	-0.15	0.0	-0.02	-0.12	0.41	0.33	0.33	0.01	-0.16	0.34	0.15	0.44	-0.14	-0.17	-0.09	0.72	0.56	0.21	0.17	0.19	-0.36		-0.09	-0.09	-0.17
Net Interest Income	0.5	-0.58	-0.43	-0.68	-0.51	-0.17	-0.55	-0.3	-0.15	-0.57	-0.22	-0.15	-0.31	0.16	-0.63	0.36	-0.12	-0.43	0.62	0.3	0.87	-0.29	-0.09		0.92	-0.9
Reconciled Depreciation	0.52	-0.59	-0.27	-0.66	-0.54	0.0	-0.43	-0.18	-0.03	-0.63	-0.08	-0.11	-0.17	0.16	-0.7	0.34	-0.2	-0.35	0.57	0.27	0.83	-0.26	-0.09	0.92		-0.84
Extraordinary Items	-0.48	0.49	0.38	0.56	0.43	0.08	0.42	0.18	0.12	0.48	0.17	0.18	0.25	-0.13	0.53	-0.31	0.04	0.28	-0.57	-0.27	-0.91	0.32	-0.17	-0.9	-0.84

Click cells to compare fundamentals

Merck Account Relationship Matchups

Merck income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Interest Expense	893M	831M	806M	962M	1.1B	1.2B
Total Revenue	46.8B	48.0B	48.7B	59.3B	59.9B	32.5B
Gross Profit	32.7B	32.5B	35.1B	41.9B	43.9B	46.1B
Operating Income	9.2B	5.4B	10.6B	14.7B	3.0B	2.8B
Ebit	9.2B	5.4B	10.6B	14.7B	3.0B	5.4B
Ebitda	12.9B	9.1B	13.9B	18.6B	6.9B	8.2B
Cost Of Revenue	14.1B	15.5B	13.6B	17.4B	16.0B	11.7B
Income Before Tax	11.5B	8.8B	13.9B	16.4B	1.9B	1.8B
Net Income	9.8B	7.1B	13.0B	14.5B	365M	346.8M
Income Tax Expense	1.7B	1.7B	1.5B	1.9B	1.5B	2.0B
Research Development	9.9B	13.6B	12.2B	13.5B	30.5B	32.1B
Minority Interest	(66M)	15M	691M	(7M)	(13M)	(12.4M)
Non Recurring	638M	578M	661M	337M	303.3M	288.1M
Tax Provision	1.7B	1.7B	1.5B	1.9B	2.8B	2.2B
Interest Income	274M	59M	1.9B	1.3B	390M	732.6M
Net Interest Income	(619M)	(772M)	(770M)	(805M)	(681M)	(715.1M)

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Merck Company is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Merck Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Merck Company Stock. Highlighted below are key reports to facilitate an investment decision about Merck Company Stock:

How To Invest In Merck

Details

Is Merck Stock a good investment?

Details

What is Merck's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Merck Valuation and Merck Correlation analysis.

You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.

Complementary Tools for Merck Stock analysis

When running Merck's price analysis, check to measure Merck's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merck is operating at the current time. Most of Merck's value examination focuses on studying past and present price action to predict the probability of Merck's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merck's price. Additionally, you may evaluate how the addition of Merck to your portfolios can decrease your overall portfolio volatility.

	Share Portfolio Track or share privately all of your investments from the convenience of any device
	Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk
	Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
	Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios
	Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk
	Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
	Portfolio Anywhere Track or share privately all of your investments from the convenience of any device
	Money Managers Screen money managers from public funds and ETFs managed around the world

Is Merck's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Merck. If investors know Merck will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Merck listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.453

Dividend Share

2.92

Earnings Share

0.14

Revenue Per Share

23.695

Quarterly Revenue Growth

0.058

The market value of Merck Company is measured differently than its book value, which is the value of Merck that is recorded on the company's balance sheet. Investors also form their own opinion of Merck's value that differs from its market value or its book value, called intrinsic value, which is Merck's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Merck's market value can be influenced by many factors that don't directly affect Merck's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Merck's value and its price as these two are different measures arrived at by different means. Investors typically determine if Merck is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merck's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Merck Income Statement Research

Merck income statement Correlations

Merck Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Merck income statement Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for Merck Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Gross Profit	+ 0.97	Interest Expense
Total Operating Expenses	+ 0.97	Other Operating Expenses
Net Income	+ 0.97	Income Before Tax
Other Operating Expenses	+ 0.96	Interest Expense
Research Development	+ 0.96	Total Operating Expenses
Other Operating Expenses	+ 0.95	Gross Profit

Extraordinary Items	- 0.91	Selling And Marketing Expenses
Extraordinary Items	- 0.9	Net Interest Income
Extraordinary Items	- 0.84	Reconciled Depreciation
Non Recurring	- 0.73	Gross Profit
Reconciled Depreciation	- 0.7	Research Development
Non Operating Income Net Other	- 0.69	Gross Profit